Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 45, 2015 - Issue 1
187
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague–Dawley and Dark Agouti rats

, , &
Pages 3-9 | Received 18 May 2014, Accepted 04 Jul 2014, Published online: 22 Jul 2014

References

  • Abozguia K, Elliott P, McKenna W, et al. (2010). Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122:1562–9
  • Amoah AG, Gould BJ, Parke DV, Lockhart JD. (1986). Further studies on the pharmacokinetics of perhexiline maleate in humans. Xenobiotica 16:63–8
  • Barclay ML, Sawyers SM, Begg EJ, et al. (2003). Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 13:627–32
  • Barham HM, Lennard MS, Tucker GT. (1994). An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem Pharmacol 47:1295–307
  • Cole PL, Beamer AD, McGowan N, et al. (1990). Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 81:1260–70
  • Cooper RG, Evans DAP, Whibley EJ. (1984). Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet 21:27–33
  • Davies BJ, Herbert MK, Coller JK, et al. (2006a). Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 843:302–9
  • Davies BJ, Herbert MK, Culbert JA, et al. (2006b). Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 832:114–20
  • Davies BJ, Coller JK, Somogyi AA, et al. (2007). CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos 35:128–38
  • Davies BJ, Herbert MK, Coller JK, et al. (2008). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. Br J Clin Pharmacol 65:347–54
  • Fragasso G, Salerno A, Spoladore R, et al. (2008). Metabolic therapy of heart failure. Curr Pharm Des 14:2582–91
  • Gould BJ, Amoah AG, Parke DV. (1986). Stereoselective pharmacokinetics of perhexiline. Xenobiotica 16:491–502
  • Hiroi T, Chow T, Imaoka S, Funae Y. (2002). Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 30:970–6
  • Horowitz JD, Chirkov YY. (2010). Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation. Circulation 122:1547–9
  • Horowitz JD, Sia ST, Macdonald PS, et al. (1986). Perhexiline maleate treatment for severe angina pectoris – correlations with pharmacokinetics. Int J Cardiol 13:219–29
  • Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13
  • Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526
  • Inglis SC, Herbert MK, Davies BJ, et al. (2007). Effect of CYP2D6 metabolizer status on the disposition of the (+) and (−) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenet Genom 17:305–12
  • Jones TE, Morris RG, Horowitz JD. (2004). Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state. Br J Clin Pharmacol 57:263–9
  • Kennedy JA, Unger SA, Horowitz JD. (1996). Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52:273–80
  • Kodde IF, van der Stok J, Smolenski RT, de Jong JW. (2007). Metabolic and genetic regulation of cardiac energy substrate preference. Comp Biochem Physiol A Mol Integr Physiol 146:26–39
  • Komura H, Iwaki M. (2005). Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6. J Pharm Sci 94:397–408
  • Lee L, Campbell R, Scheuermann-Freestone M, et al. (2005). Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112:3280–8
  • Leeson GA, Lang JF, Zeiger AV, et al. (1969). Excretion, blood levels and tissue retention of perhexiline-14C maleate in dogs. Pharmacologist 11:280
  • Matsunaga E, Zanger UM, Hardwick JP, et al. (1989). The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 28:7349–55
  • Meier C, Wahllaender A, Hess CW, Preisig R. (1986). Perhexiline-induced lipidosis in the dark Agouti (DA) rat. An animal model of genetically determined neurotoxicity. Brain 109:649–60
  • Morgan MY, Reshef R, Shah RR, et al. (1984). Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25:1057–64
  • Ohishi N, Imaoka S, Suzuki T, Funae Y. (1993). Characterization of two P-450 isozymes placed in the rat CYP2D subfamily. Biochim Biophys Acta 1158:227–36
  • Poupon R, Rosenztajn L, de Saint-Maur PP, et al. (1980). Perhexiline maleate-associated hepatic injury prevalence and characterisitcs. Digestion 20:145–50
  • Sachse C, Brockmoller J, Bauer S, Roots I. (1997). Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–95
  • Sallustio BC, Westley IS, Morris RG. (2002). Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol 54:107–14
  • Schulz-Utermoehl T, Bennett AJ, Ellis SW, et al. (1999). Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 9:357–66
  • Singh A, Gilroy C, Chu I, Villeneuve DC. (1997). Toxicity of PCB 105 in the rat liver: an ultrastructural and biochemical study. Ultrastruct Pathol 21:143–51
  • Singlas E, Goujet MA, Simon P. (1978). Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol 14:195–201
  • Unger SA, Robinson MA, Horowitz JD. (1997). Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust N Z J Med 27:24–8
  • Willoughby SR, Stewart S, Chirkov YY, et al. (2002). Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J 23:1946–54
  • Wright GJ, Leeson GA, Zeiger AV, Lang JF. (1973). The absorption, excretion and metabolism of perhexiline maleate by the human. Postgrad Med J 49:8–15
  • Yamamoto Y, Tasaki T, Nakamura A, et al. (1998). Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics 8:73–82
  • Zanger UM, Raimundo S, Eichelbaum M. (2004). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23–37
  • Zysset T, Zeugin T, Kupfer A. (1988). In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochem Pharmacol 37:3155–60

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.